The recent news that the drug olaparib delayed the progress of advanced pancreatic cancer in patients who have faults in the BRCA1 and 2 genes underlines the relevance and importance of a PCRF-funded research project being carried out by Dr Mairéad McNamara from the University of Manchester and The Christie NHS Foundation Trust.
A ‘precision drug’ designed to target specific genetic faults within cancer cells has caused cautious excitement, by delaying the progression of some advanced pancreatic cancers after chemotherapy treatment.
Seven innovative research projects tackling pancreatic cancer have been awarded grants by the national charity Pancreatic Cancer Research Fund (PCRF) totalling £1.2M.
The first study in the world to take a detailed look at scar tissue that surrounds pancreatic cancer tumours – also known as the stroma - has revealed a range of different scar tissue types that could help clinicians predict which patients will respond best to particular treatments.
A new technique to study tissue samples in 3D has revealed that pancreatic cancers can start and grow in two distinct ways, solving a decades-old mystery of how tumours form.
Research supported by Pancreatic Cancer Research Fund reports that mice with pancreatic cancer survived almost twice as long if they were given a constituent of medicinal cannabis alongside chemotherapy.
Patients who have donated their pancreatic tumour tissue to the PCRF Tissue Bank following surgery and their families were among a group of supporters who took part in a patient and public engagement event at Barts Cancer Institute on 02 July.
Recent results from a study being conducted by US company, Grail, reveal that its ‘liquid biopsy’ analysis of blood samples is showing promise in diagnosing a number of cancers – including pancreatic – in their early stages.